Literature DB >> 18816591

Clinical features of late-onset Pompe disease: a prospective cohort study.

John H J Wokke1, Diana M Escolar, Alan Pestronk, Kenneth M Jaffe, Gregory T Carter, Leonard H van den Berg, Julaine M Florence, Jill Mayhew, Alison Skrinar, Deyanira Corzo, Pascal Laforet.   

Abstract

The objective of this 12-month study was to describe the clinical features of late-onset Pompe disease and identify appropriate outcome measures for use in clinical trials. Assessments included quantitative muscle testing (QMT), functional activities (FAA), 6-min walk test (6MWT), and pulmonary function testing (PFT). Percent predicted values indicated quantifiable upper and lower extremity weakness, impaired walking ability, and respiratory muscle weakness. Significant declines in arm and leg strength and pulmonary function were observed during the study period. The outcome measures were demonstrated to be safe and reliable. Symptom duration was identified as the best predictor of the extent of skeletal and respiratory muscle weakness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18816591     DOI: 10.1002/mus.21025

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  44 in total

1.  Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.

Authors:  S Strothotte; N Strigl-Pill; B Grunert; C Kornblum; K Eger; C Wessig; M Deschauer; F Breunig; F X Glocker; S Vielhaber; A Brejova; M Hilz; K Reiners; W Müller-Felber; E Mengel; M Spranger; Benedikt Schoser
Journal:  J Neurol       Date:  2009-08-01       Impact factor: 4.849

Review 2.  Pompe Disease: From Basic Science to Therapy.

Authors:  Lara Kohler; Rosa Puertollano; Nina Raben
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

3.  Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning.

Authors:  Manuela Corti; Brian Cleaver; Nathalie Clément; Thomas J Conlon; Kaitlyn J Faris; Gensheng Wang; Janet Benson; Alice F Tarantal; Davis Fuller; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2015-09       Impact factor: 5.032

4.  Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype.

Authors:  L E M van den Berg; M R Drost; G Schaart; J de Laat; P A van Doorn; A T van der Ploeg; A J J Reuser
Journal:  J Inherit Metab Dis       Date:  2012-10-11       Impact factor: 4.982

5.  Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.

Authors:  Mugdha V Rairikar; Laura E Case; Lauren A Bailey; Zoheb B Kazi; Ankit K Desai; Kathryn L Berrier; Julie Coats; Rachel Gandy; Rebecca Quinones; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-09-19       Impact factor: 4.797

6.  Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease.

Authors:  J C van der Meijden; D Güngör; M E Kruijshaar; A D J Muir; H A Broekgaarden; A T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2014-08-12       Impact factor: 4.982

7.  Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months.

Authors:  Ilka Schneider; Frank Hanisch; Tobias Müller; Bernd Schmidt; Stephan Zierz
Journal:  Wien Med Wochenschr       Date:  2012-11-19

8.  Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study.

Authors:  Laura Deroma; Mattia Guerra; Annalisa Sechi; Giovanni Ciana; Giorgia Cisilino; Andrea Dardis; Bruno Bembi
Journal:  Eur J Pediatr       Date:  2014-01-07       Impact factor: 3.183

Review 9.  Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.

Authors:  Gauthier Remiche; Dario Ronchi; Francesca Magri; Costanza Lamperti; Andreina Bordoni; Maurizio Moggio; Nereo Bresolin; Giacomo P Comi
Journal:  J Neurol       Date:  2013-10-25       Impact factor: 4.849

10.  The brain in late-onset glycogenosis II: a structural and functional MRI study.

Authors:  Barbara Borroni; M S Cotelli; E Premi; S Gazzina; M Cosseddu; A Formenti; R Gasparotti; M Filosto; A Padovani
Journal:  J Inherit Metab Dis       Date:  2013-04-23       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.